Exit Centocor, Enter Fujirebio
Executive Summary
Centocor's sale of its oncology diagnostics business to Fujirebio Inc. of Japan marks the end of an era for Centocor and the beginning of a new expansionist strategy at Fujirebio. Centocor wants to concentrate its resources on its flourishing pharmaceuticals business, while Fujirebio is eager to expand its diagnostics business globally.